Influvac

influenza virus vaccine, the active ingredient in Influvac, is an inactivated influenza vaccine presented as a solution for injection for intramuscular, subcutaneous use. It prevents influenza infection caused by influenza A and B viruses in individuals at risk.

GNH USA supplies Influvac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac is an inactivated influenza vaccine used to prevent infection by influenza A and B viruses.

- Seasonal Influenza: provides active immunity to reduce the risk of contracting flu during the annual season. - Children (≥6 months): protects young patients from influenza‑related illness. - High‑Risk Groups: lowers the chance of severe complications in people with chronic medical conditions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: localized erythema or edema that resolves within a few days. - Low‑grade fever: transient temperature rise often accompanied by mild headache or muscle aches.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder that may develop weeks after vaccination. - Seizures: infrequent occurrence, particularly in children with a history of febrile seizures.

Influvac should be administered after careful assessment of the individual's medical history.

- Allergy assessment: avoid if the patient has a severe allergic reaction to any vaccine component. - Guillain‑Barré history: evaluate risk and consider alternative protection strategies. - Pregnancy: safety data are limited; use only if the potential benefit outweighs the risk. - Immunocompromised patients: vaccine may elicit a reduced immune response; monitor effectiveness. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other agents that affect immune function.

Major Interactions (Avoid): - Live vaccines: do not administer concurrently with live attenuated vaccines. - Immunoglobulins or blood products: may diminish vaccine‑induced immunity if given within 3 months. - Antiviral therapy (e.g., oseltamivir) started within 48 h of vaccination: can reduce antibody response.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: monitor serologic response as efficacy may be lowered. - Antipyretics taken before vaccination: may blunt the immune response; advise use after injection if needed. - Other injectable vaccines given same day: observe for additive local or systemic reactions.